Pancreatic Cancer research hub

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

This study is for people who have had surgery for pancreatic cancer. We are testing a new drug, daraxonrasib, to see if it can stop the cancer from coming back, compared to just being watched. It's to help see if this new treatment works better.